Phase i/II trial of ONC201 for the treatment of multiple myeloma IND121,496 (01/05/2015)
Ended Project Grant Awarded Last action
- Award ID
- R01FD005402
- Recipient
-
Oncoceutics, Inc. UEI ZKPGUP3MLBW9 Part of Chimerix, Inc.
- Awarding agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Obligated
- $1,242,857
Award facts
- Assistance listing
- 93.103 Food and Drug Administration Research
- Completion date
- Originally
- Funding agency
- Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
- Place of performance
- Hummelstown, PA 17036, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $496,507 | |
| Amendment | $496,399 | |
| Amendment | $0 | |
| Original award | $249,951 |
Quick answers
Who received award R01FD005402?
R01FD005402 was awarded to Oncoceutics, Inc. by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on August 10, 2016.
How much is award R01FD005402 worth?
$1,242,857 has been obligated on R01FD005402.
Which agency awarded R01FD005402?
FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD005402, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award